Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10920881 | 0.84 | ALDH1A1 (0.57) | PLA2G4BALDH1A1MAPTLMNAHPGD | |
| SCHEMBL182622 | 0.83 | RAB9A (0.56) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL14038390 | 0.83 | ALDH1A1 (0.55) | PLA2G4BALDH1A1MAPTLMNAHPGD | |
| SCHEMBL27828649 | 0.82 | ALDH1A1 (0.57) | PLA2G4BALDH1A1MAPTLMNAHPGD | |
| SCHEMBL4173572 | 0.81 | PLA2G4B (0.47) | PLA2G4BALDH1A1MAPTLMNAHPGD | |
| SCHEMBL6813683 | 0.81 | LMNA (0.46) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL27606455 | 0.81 | ALDH1A1 (0.53) | PLA2G4BALDH1A1MAPTLMNAHPGD | |
| SCHEMBL6960 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL27868404 | 0.80 | MAPT (0.49) | PLA2G4BALDH1A1MAPTLMNAHPGD | |
| SCHEMBL18155122 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPTLMNAHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975862-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975862-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| CN-106045936-A | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | 雷维瓦药品公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-2400968-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2400968-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | Reviva Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2299814-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010099502-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099502-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, GRIK2 | PLA2G4B 1566/4885ALDH1A1 163/4885MAPT 2251/4885 |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | PLA2G4B 2384/4885ALDH1A1 860/4885MAPT 692/4885 |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | GRIK5, HTR5A, KYNU | PLA2G4B 2087/4885ALDH1A1 623/4885MAPT 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.